Questi sono gli anticorpi monoclonali che l’Ue liberalizzerà e saranno disponibili (si spera) in tutti gli ospedali d’Europa:
1) baricitinib immunosuppresant (a medicine that reduces the activity of the immune system) from Eli Lilly: an application for extension of marketing authorisation for COVID-19 indication is under assessment
2) combination of bamlanivimab and etesevimab from Eli Lilly: under rolling review
3) combination of casirivimab and imdevimab from Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd: under rolling review
4) regdanvimab from Celltrion: under rolling review
5) sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc.: under rolling review
